For pharma IP teams, portfolio managers, R&D leads, and institutional investors operating in or entering the Russian market. 1. Why […]
Russia’s Pharmaceutical Patent Term Extensions: The Complete IP Strategy Playbook Read Post »
I. Why This Document Exists Every blockbuster drug that has generated a billion-dollar revenue stream in the past three decades
The $230 Billion Subsidy: How Government Patent Data Drives Biopharma IP Strategy Read Post »
In the early months of the pandemic, when much of the economy was idling, an unusual silence fell over another
Bloomberg and Drug PatentWatch: A “Perfect Storm” Affecting Generic Drugs Read Post »
Off-patent drugs represent one of the most systematically underexploited categories in the pharmaceutical IP landscape. Their pharmacology is known. Their
A technically dense, data-grounded analysis of repurposing economics, IP valuation, regulatory pathways, computational platforms, and lifecycle management tactics for existing
Drug Repurposing: The Definitive Strategic Guide Read Post »
Why Patents Are the Wrong Starting Point Most analysts open a pharma investment thesis by pulling Orange Book listings and
What Actually Drives Pharma Returns: 10 Non-Patent Factors Every Investor Needs to Model Read Post »
1. Executive Summary FDA approval of a generic drug is a regulatory milestone, not a commercial launch date. The gap
Part I: US Pharmaceutical Market — Scale, Structural Drivers, and the 2025 Inflection Point Market Size Reality Check: Reconciling Competing
Introduction: The $2 Billion Data Problem Start with the math. A new drug costs roughly $2 billion and a decade
Chemical Databases in Drug Discovery: The Complete IP and R&D Intelligence Playbook Read Post »
Sign in or create a free account to read this DrugPatentWatch article
